Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc.
about
Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapyLamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapyPrevention of Hepatitis B reactivation in the setting of immunosuppressionManagement of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesAcute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis BReactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.Novel double-antigen sandwich immunoassay for human hepatitis B core antibody.Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients.Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance.Hepatitis B in transplantation.Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management.Late HBsAg seroreversion of mutated hepatitis B virus after bone marrow transplantationManagement of occult hepatitis B virus infection: an update for the clinician.Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation.Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation.Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.Screening for hepatitis B in patients with lymphoma.Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study.Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely.Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management.Occult hepatitis B virus infection: a covert operation.Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis.Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients.How to achieve immune control in chronic hepatitis B?Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy.Occult hepatitis B virus infection in hemodialysis patients in Japan.Occult hepatitis B virus infection: a case of reactivation in a patient receiving immunosuppressive treatment for allogeneic bone marrow transplantation.Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infecRisk of hepatitis B infection in pediatric acute lymphoblastic leukemia in a tertiary care center from South India.Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.JSH Guidelines for the Management of Hepatitis B Virus Infection.Changes in levels of hepatitis B virus markers in patients positive for low-titer hepatitis B surface antigen.Hepatitis B reactivation after chemotherapy: two decades of clinical research.Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.Histological improvement with lamivudine therapy for de novo hepatitis B occurring in an anti-HBs-positive child after bone marrow transplantation.Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT.
P2860
Q24240881-827DAF19-881E-44B3-A97A-51DCA7FDDAF6Q24245239-824DB063-CFAF-4070-B8EC-2E7D65885B90Q26747023-13DFD84A-93EB-44E6-B9F2-B6537B226310Q27000080-EEF26404-B00A-4D8C-81CB-8CFE22CA0974Q27022622-984FCE3E-DB4C-4553-AD28-05B19C8D4A4BQ30434625-19463095-B406-4B30-9671-6502642E724DQ33526947-72FBADD8-FFD6-4E77-B61E-2E01BEC5861AQ33782078-D2FF162B-9AEA-4CA8-8658-6F6CE5FF1648Q34013180-43B12CE4-CEAC-49F7-A74F-FF1B70554FDFQ34294933-E482ECF6-4196-42E0-B72F-8F9A25CEF2F6Q34394777-02E04880-95B2-4A65-A119-CAF3E7D084E4Q34725624-8810B054-3AC2-4250-A55C-0B6F02698FE9Q34757408-7CDBE9A4-E958-4C88-95E7-11A910C403EEQ35047635-B292F929-0F64-447D-B48D-D21019A2A9B1Q35210407-4B1D73E5-31C5-45F5-AE85-2076FE861306Q35375654-42099104-1FBF-496B-9DAF-3C9CAB655185Q35567748-D5B7D1C2-8B12-4C8C-8B0A-72C3A51C4709Q36058282-0ACE58EB-25ED-4C7C-AFF1-989A65082218Q36195013-975F7C0C-DE85-47F0-B26E-FF6D92831022Q36752181-12132BC6-D10A-4DA4-863A-DFEF80229473Q36898145-59FCC3D6-CF08-4B42-BFB8-D5ACA4F03277Q36951280-E3B1AE8E-E670-4941-AB37-C84C9B5DB29AQ37650888-4BB81EB6-B037-41F5-95E5-5B0B610ADBD3Q37798175-4AFE7D12-07A5-49C1-BCA6-64CACDDF8FDBQ37842669-703A7979-6A8C-4175-8766-8990481AE068Q37942651-823E6AA2-F83A-4C4B-8E77-4C56BE4360B7Q38383489-788334AA-2705-47D5-A405-18A261BE82E7Q39034118-DB99843A-A078-40CE-9E0C-14204DCDDCB5Q39603233-8124AF8A-AA95-4355-B632-8DEA712349DAQ41680435-CFF018A8-B863-4955-8490-788F92051C1DQ41779103-E29E25A6-DB1A-4ECF-897D-E2E3A1F17D02Q42198103-86E88BAB-6140-4B62-909A-8BBB7951D524Q42220392-F2D9FF00-34DF-465E-B5DE-B93980680A15Q42224704-3FAB2425-A29B-48CD-84C4-F16A5F97A5E2Q42244740-09D25B75-6A75-4FBD-BF90-FE66D943FF98Q42285230-981C11C2-6EB0-4119-AD41-04B61BDC8043Q42590960-2935B888-90F1-4942-AEF9-515B0707810FQ43225446-0C9285A1-11D9-4E59-BECD-56A5B95B5ED0Q44171006-43F12A66-9501-4432-ACAA-FA65C5A0A674Q44239280-D4167CA0-32EB-49CE-99F3-23DBF379960A
P2860
Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc.
description
1998 nî lūn-bûn
@nan
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Reverse seroconversion of hepa ...... nsplant anti-HBs and anti-HBc.
@en
Reverse seroconversion of hepa ...... nsplant anti-HBs and anti-HBc.
@nl
type
label
Reverse seroconversion of hepa ...... nsplant anti-HBs and anti-HBc.
@en
Reverse seroconversion of hepa ...... nsplant anti-HBs and anti-HBc.
@nl
prefLabel
Reverse seroconversion of hepa ...... nsplant anti-HBs and anti-HBc.
@en
Reverse seroconversion of hepa ...... nsplant anti-HBs and anti-HBc.
@nl
P2093
P1433
P1476
Reverse seroconversion of hepa ...... nsplant anti-HBs and anti-HBc.
@en
P2093
Bernaudin F
Cordonnier C
Metreau JM
P304
P356
10.1097/00007890-199809150-00012
P577
1998-09-01T00:00:00Z